

Emcure Net Surges as Local Biz Grows 25%

Our Bureau

Mumbai: Emcure Pharmaceuticals has reported a 63% year-on-year jump in fourth quarter consolidated net profit, boosted by robust performance across its domestic and international businesses.

The Pune-based company on Thursday said March-quarter consolidated net profit stood at ₹197 crore, while revenue from operations stood at ₹2,116 crore, up 19.5% from a year ago.

In a filing to the stock exchanges, Emcure said its earnings before interest, tax, depreciation and amortisation (Ebitda) rose by 25.2% year-on-year, while its Ebitda margin stood at 18.4%.

Emcure's domestic business grew by 24.8% year-on-year, led by its women's health and cardio franchises, and further aided by its new focus areas of dermatology and over-the-counter (OTC).

Its international business registered a growth of 15.6%, led by a

39.3% growth in the rest of the world segment. In Europe, the company recently acquired a portfolio of products and secured key regulatory approvals.

"Over the past year we have effectively executed our strategies across both domestic and interna-

tional markets. On domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches," said Satish Mehta, chief executive and managing director of Emcure.

"In the international markets, we are seeing approvals for our differentiated product offerings," he said. "Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies."

The company's domestic business sales stood at ₹929 crore, up 24.8%.

63%
Rise in net
profit in Q4

20%
Rise in
revenue